Title of Study: A randomised, double-blind, parallel group, placebo-controlled Phase 3 study to assess the efficacy and safety of OLAPARIB versus PLACEBO as adjuvant treatment in patients with germline BRCA 1/2 mutations and high risk HER2-negative primary breast cancer who have completed definitive local treatment and neoadjuvant or adjuvant chemotherapy
Patient Population: Germline BRCA 1/2 mutations and high risk HER2- primary breast cancer
Locations: Edmonton, Vancouver, Winnipeg, Hamilton, Toronto, Québec, Montreal, Greenfield Park
Click HERE for more information.
Title of Study: A Phase 3 randomized study to investigate the efficacy and safety of ATEZOLIZUMAB in combination with neoadjuvant ANTHRACYCLINE/NAB-PACLITAXEL-based chemotherapy compared with PLACEBO and chemotherapy in patients with primary invasive triple negative breast cancer
Patient Population: triple negative primary breast cancer
Locations: Oshawa, Québec, Montreal
Click HERE for more information.
Title of Study: PALbociclib CoLlaborative Adjuvant Study: A randomized Phase III trial of palbociclib with standard adjuvant endocrine therapy versus standard adjuvant endocrine therapy alone for hormone receptor positive (HR+) / Human Epidermal Growth Factor Receptor 2 (HER2) – negative early breast cancer
Patient Population: Pre and postmenopausal women or men with stage II or stage III early invasive breast cancer that’s ER+ and/or PR+ and HER2-.
Locations: Abbotsford, Kelowna, Vancouver, Winnipeg, Saint John, Halifax, Kitchener, Hamilton, Toronto (PMH & Sunnybrook), Quebec, St. Catharines, Sherbrooke, Montreal (CHUM, Jewish General Hospital, MUHC Glen site), Saskatoon
Click HERE for more information
Photo by rawpixel.com on Unsplash
Receive updates by email 
